Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Policy / Regulatory

Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025

Fineline Cube Feb 20, 2025

In a significant move to bolster foreign investment and enhance the country’s economic openness, the...

Company Deals

Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research

Fineline Cube Feb 20, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China

Fineline Cube Feb 20, 2025

China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the...

Company Drug

Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease

Fineline Cube Feb 20, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...

Company Drug

Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC

Fineline Cube Feb 20, 2025

Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a...

Company Deals

Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens

Fineline Cube Feb 20, 2025

UK-based RNA immunotherapy developer Epitopea announced a licensing and research cooperation agreement with US pharmaceutical...

Company Drug

Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC

Fineline Cube Feb 20, 2025

Germany-based Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has accepted its...

Company Drug

Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study

Fineline Cube Feb 20, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...

Company Drug

Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia

Fineline Cube Feb 20, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that its biosimilar of Roche’s Avastin (bevacizumab), Hanbeitai,...

Company Drug

Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML

Fineline Cube Feb 20, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503, OTCMKTS: ALPMY ) announced that the National Medical Products...

Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study

Fineline Cube Feb 20, 2025

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...

Company Medical Device

Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement

Fineline Cube Feb 20, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received marketing approval from...

Company Deals

Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development

Fineline Cube Feb 20, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...

Company

Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment

Fineline Cube Feb 20, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...

Company Deals

Jiangxi Rimag Group and Xunfei Healthcare Form Strategic Alliance for Smart Healthcare

Fineline Cube Feb 20, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced a strategic alliance with Xunfei Healthcare...

Company Deals

Rendu Biotechnology Partners with Green Apple Medical System for RNA Diagnostics Expansion

Fineline Cube Feb 20, 2025

Rendu Biotechnology Co., Ltd., (SHA: 688193) a Shanghai-based specialist in RNA molecular diagnostics, has entered...

Company Deals

Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline

Fineline Cube Feb 20, 2025

China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...

Company Legal / IP

AstraZeneca Faces Class Action Lawsuits Over China Legal Issues

Fineline Cube Feb 20, 2025

AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...

Company Deals Drug

Biogen Licenses Stoke Therapeutics’ Zorevunersen for Dravet Syndrome Outside Americas

Fineline Cube Feb 19, 2025

US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc....

Company Drug

TAHO Pharma’s TAH3311 Oral Film Shows Bioequivalence to Eliquis in Study

Fineline Cube Feb 19, 2025

Taiwan-based TAHO Pharmaceuticals announced positive preliminary results from a pivotal study for its TAH3311 oral...

Posts pagination

1 … 146 147 148 … 602

Recent updates

  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
  • NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.